These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 12010664

  • 1. Dose intensification with autologous stem cell transplantation in relapsed and resistant Hodgkin's disease.
    Anselmo AP, Cavalieri E, Meloni G, Alimena G, Cantonetti M, Maurizi Enrici R, Tosti ME, Falchetto Osti M, Gianfelici V, Mandelli F.
    Haematologica; 2002 May; 87(5):507-11. PubMed ID: 12010664
    [Abstract] [Full Text] [Related]

  • 2. Salvage chemotherapy with mini-BEAM for relapsed or refractory Hodgkin's disease prior to autologous peripheral blood stem cell transplantation.
    Fernández-Jiménez MC, Canales MA, Ojeda E, de Bustos JG, Aguado MJ, Hernández-Navarro F.
    Haematologica; 1999 Nov; 84(11):1007-11. PubMed ID: 10553161
    [Abstract] [Full Text] [Related]

  • 3. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A, Hardan I, Shpilberg O, Raanani P, Grotto I, Ben-Bassat I.
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [Abstract] [Full Text] [Related]

  • 4. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B, Koc Y, Ozdemir E, Kars A, Turker A, Tekuzman G, Kansu E.
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [Abstract] [Full Text] [Related]

  • 5. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL, Tani M, Molinari AL, Stefoni V, Zuffa E, Alinari L, Gabriele A, Bonifazi F, Salvucci M, Tura S, Baccarani M.
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [Abstract] [Full Text] [Related]

  • 6. 'Relative' chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma.
    Chen CI, Roitman D, Tsang R, Stewart AK, Keating A, Crump M.
    Bone Marrow Transplant; 2002 Dec; 30(12):885-91. PubMed ID: 12476281
    [Abstract] [Full Text] [Related]

  • 7. Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR).
    Lazarus HM, Loberiza FR, Zhang MJ, Armitage JO, Ballen KK, Bashey A, Bolwell BJ, Burns LJ, Freytes CO, Gale RP, Gibson J, Herzig RH, LeMaistre CF, Marks D, Mason J, Miller AM, Milone GA, Pavlovsky S, Reece DE, Rizzo JD, van Besien K, Vose JM, Horowitz MM.
    Bone Marrow Transplant; 2001 Feb; 27(4):387-96. PubMed ID: 11313668
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Société Française de Greffe de Moëlle.
    Brice P, Bouabdallah R, Moreau P, Divine M, André M, Aoudjane M, Fleury J, Anglaret B, Baruchel A, Sensebe L, Colombat P.
    Bone Marrow Transplant; 1997 Jul; 20(1):21-6. PubMed ID: 9232251
    [Abstract] [Full Text] [Related]

  • 9. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY, Shi YK, He XH, Han XH, Liu P, Yang JL, Zhou AP, Feng FY.
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [Abstract] [Full Text] [Related]

  • 10. Autologous stem cell transplantation for poor prognosis Hodgkin's disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group.
    Sureda A, Mataix R, Hernández-Navarro F, Jarque I, Lahuerta JJ, Tomás JF, Brunet S, Caballero D, Conde E, León A, Fernández MN, López A, Maldonado J, Bengoechea E, Callís M, Carrera D, García-Conde J, García-Laraña J, Moraleda JM, Morey M, Rifón J, Sierra J, Torres A, Domingo-Albós A.
    Bone Marrow Transplant; 1997 Aug; 20(4):283-8. PubMed ID: 9285542
    [Abstract] [Full Text] [Related]

  • 11. Second autologous stem cell transplant for multiply relapsed Hodgkin's disease.
    Lin TS, Avalos BR, Penza SL, Marcucci G, Elder PJ, Copelan EA.
    Bone Marrow Transplant; 2002 May; 29(9):763-7. PubMed ID: 12040474
    [Abstract] [Full Text] [Related]

  • 12. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo.
    Majolino I, Vignetti M, Meloni G, Vegna ML, Scimè R, Tringali S, Amaddii G, Coser P, Tribalto M, Raimondi R, Bergonzi C, Sajeva MR, Sica S, Ferrando F, Messina G, Mandelli F.
    Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460
    [Abstract] [Full Text] [Related]

  • 13. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [Abstract] [Full Text] [Related]

  • 14. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP, Stiff PJ, Toor AA, Parthasarathy M.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [Abstract] [Full Text] [Related]

  • 15. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [Abstract] [Full Text] [Related]

  • 16. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 17. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence.
    Tarella C, Cuttica A, Vitolo U, Liberati M, Di Nicola M, Cortelazzo S, Rosato R, Rosanelli C, Di Renzo N, Musso M, Pavone E, Santini G, Pescarollo A, De Crescenzo A, Federico M, Gallamini A, Pregno P, Romano R, Coser P, Gallo E, Boccadoro M, Barbui T, Pileri A, Gianni AM, Levis A.
    Cancer; 2003 Jun 01; 97(11):2748-59. PubMed ID: 12767087
    [Abstract] [Full Text] [Related]

  • 18. Progressive disease after ABMT for Hodgkin's disease.
    Bolwell BJ, Kalaycio M, Goormastic M, Dannley R, Andresen SW, Lichtin A, Overmoyer B, Pohlman B.
    Bone Marrow Transplant; 1997 Nov 01; 20(9):761-5. PubMed ID: 9384478
    [Abstract] [Full Text] [Related]

  • 19. Primary refractory Hodgkin's lymphoma: outcome after high-dose chemotherapy and autologous SCT and impact of various prognostic factors on overall and event-free survival. A single institution result of 66 patients.
    Akhtar S, El Weshi A, Abdelsalam M, Hussaini H, Janabi I, Rahal M, Maghfoor I.
    Bone Marrow Transplant; 2007 Oct 01; 40(7):651-8. PubMed ID: 17660837
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.
    Ai Zheng; 2006 Apr 01; 25(4):486-9. PubMed ID: 16613686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.